Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | BCL9 | O00512 | 1/20 | 0.49 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.42 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.42 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11423467 | 0.88 | GAA (0.50) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL27126 | 0.88 | HTR2A (0.54) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL21097121 | 0.85 | HTR2A (0.54) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL21098059 | 0.85 | HTR2A (0.54) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL23922815 | 0.85 | HTR2A (0.54) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL1059539 | 0.84 | HTR2A (0.60) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL2235343 | 0.82 | HTR2A (0.52) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL2233306 | 0.82 | HTR2A (0.54) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL1242235 | 0.81 | HTR2A (0.54) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL30871778 | 0.81 | HTR2A (0.53) | HTR2AGAABCL9CTNNB1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3075722-A1 | GABA CONJUGATES AND METHODS OF USE THEREOF | Xgene Pharmaceutical Inc (KY) | 2016-10-05 | — | — | EP | disclosed |
| US-20160256558-A1 | GABA CONJUGATES AND METHODS OF USE THEREOF | KYPHIA PHARMACEUTICALS, INC. (KY) | 2016-09-08 | — | — | US | disclosed |
| US-20160256558-A1 | GABA CONJUGATES AND METHODS OF USE THEREOF | KYPHIA PHARMACEUTICALS, INC. (KY) | 2016-09-08 | — | — | US | disclosed |
| EP-2344447-B1 | GABA CONJUGATES AND METHODS OF USE THEREOF | XGENE PHARMACEUTICAL INC (KY) | 2016-06-08 | — | — | EP | disclosed |
| US-9186341-B2 | GABA conjugates and methods of use thereof | KYPHIA PHARMACEUTICALS, INC. (KY) | 2015-11-17 | — | — | US | disclosed |
| US-9186341-B2 | GABA conjugates and methods of use thereof | KYPHIA PHARMACEUTICALS, INC. (KY) | 2015-11-17 | — | — | US | disclosed |
| WO-2015137680-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING STROKE AND SYSTEMIC EMBOLISM | 동아에스티 주식회사 | 2015-09-17 | — | — | WO | disclosed |
| US-20130035352-A1 | GABA CONJUGATES AND METHODS OF USE THEREOF | KYPHIA PHARMACEUTICALS, INC. (KY) | 2013-02-07 | — | — | US | disclosed |
| US-20130035352-A1 | GABA CONJUGATES AND METHODS OF USE THEREOF | KYPHIA PHARMACEUTICALS, INC. (KY) | 2013-02-07 | — | — | US | disclosed |
| US-8268887-B2 | Drug conjugates and methods of use thereof | KYPHIA PHARMACEUTICALS, INC. (KY) | 2012-09-18 | — | — | US | disclosed |
| US-8268887-B2 | Drug conjugates and methods of use thereof | KYPHIA PHARMACEUTICALS, INC. (KY) | 2012-09-18 | — | — | US | disclosed |
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
| EP-2361910-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-08-31 | — | — | EP | disclosed |
| US-20100113497-A1 | GABA CONJUGATES AND METHODS OF USE THEREOF | KYPHIA PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113497-A1 | GABA CONJUGATES AND METHODS OF USE THEREOF | KYPHIA PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| WO-2010042759-A2 | GABA CONJUGATES AND METHODS OF USE THEREOF | KYPHIA PHARMACEUTICALS INC (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035352-A1 | GABA CONJUGATES AND METHODS OF USE THEREOF | GABRA5, GABRB3, GABRB2 | HTR2A 560/4885GAA 516/4885BCL9 4156/4885 |
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAF1, TAF5, TAF11 | HTR2A 4341/4885GAA 1535/4885BCL9 2611/4885 |
| US-20160256558-A1 | GABA CONJUGATES AND METHODS OF USE THEREOF | GABRA5, GABRB3, GABRB2 | HTR2A 560/4885GAA 516/4885BCL9 4156/4885 |
| US-20100113497-A1 | GABA CONJUGATES AND METHODS OF USE THEREOF | GABRA5, GABRB3, GABRB2 | HTR2A 560/4885GAA 516/4885BCL9 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.